GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (FRA:MR4) » Definitions » Piotroski F-Score

Meridian Bioscience (FRA:MR4) Piotroski F-Score : 0 (As of Apr. 25, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Meridian Bioscience has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Meridian Bioscience's Piotroski F-Score or its related term are showing as below:


Meridian Bioscience Piotroski F-Score Historical Data

The historical data trend for Meridian Bioscience's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Piotroski F-Score Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 6.00 7.00 4.00

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 5.00 5.00 5.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Net Income was 13.576 + 26.107 + -6.942 + 5.762 = €38.5 Mil.
Cash Flow from Operations was 31.466 + 27.619 + 13.624 + 2.007 = €74.7 Mil.
Revenue was 78.182 + 100.998 + 64.111 + 66.332 = €309.6 Mil.
Gross Profit was 43.506 + 62.177 + 34.745 + 34.332 = €174.8 Mil.
Average Total Assets from the begining of this year (Sep21)
to the end of this year (Sep22) was
(382.264 + 405.896 + 428.403 + 440.768 + 467.728) / 5 = €425.0118 Mil.
Total Assets at the begining of this year (Sep21) was €382.3 Mil.
Long-Term Debt & Capital Lease Obligation was €29.4 Mil.
Total Current Assets was €212.7 Mil.
Total Current Liabilities was €58.5 Mil.
Net Income was 22.012 + 22.094 + 9.685 + 5.658 = €59.4 Mil.

Revenue was 76.378 + 71.622 + 52.714 + 64.773 = €265.5 Mil.
Gross Profit was 50.592 + 48.528 + 30.802 + 38.009 = €167.9 Mil.
Average Total Assets from the begining of last year (Sep20)
to the end of last year (Sep21) was
(344.067 + 348.47 + 368.902 + 370.653 + 382.264) / 5 = €362.8712 Mil.
Total Assets at the begining of last year (Sep20) was €344.1 Mil.
Long-Term Debt & Capital Lease Obligation was €54.3 Mil.
Total Current Assets was €163.9 Mil.
Total Current Liabilities was €40.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Meridian Bioscience's current Net Income (TTM) was 38.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Meridian Bioscience's current Cash Flow from Operations (TTM) was 74.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep21)
=38.503/382.264
=0.10072358

ROA (Last Year)=Net Income/Total Assets (Sep20)
=59.449/344.067
=0.17278321

Meridian Bioscience's return on assets of this year was 0.10072358. Meridian Bioscience's return on assets of last year was 0.17278321. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Meridian Bioscience's current Net Income (TTM) was 38.5. Meridian Bioscience's current Cash Flow from Operations (TTM) was 74.7. ==> 74.7 > 38.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=29.418/425.0118
=0.0692169

Gearing (Last Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=54.342/362.8712
=0.14975562

Meridian Bioscience's gearing of this year was 0.0692169. Meridian Bioscience's gearing of last year was 0.14975562. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep22)=Total Current Assets/Total Current Liabilities
=212.703/58.531
=3.634023

Current Ratio (Last Year: Sep21)=Total Current Assets/Total Current Liabilities
=163.886/40.083
=4.08866602

Meridian Bioscience's current ratio of this year was 3.634023. Meridian Bioscience's current ratio of last year was 4.08866602. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Meridian Bioscience's number of shares in issue this year was 44.81. Meridian Bioscience's number of shares in issue last year was 44.03. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=174.76/309.623
=0.56442835

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=167.931/265.487
=0.63253945

Meridian Bioscience's gross margin of this year was 0.56442835. Meridian Bioscience's gross margin of last year was 0.63253945. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep21)
=309.623/382.264
=0.80997164

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep20)
=265.487/344.067
=0.77161425

Meridian Bioscience's asset turnover of this year was 0.80997164. Meridian Bioscience's asset turnover of last year was 0.77161425. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Meridian Bioscience has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Meridian Bioscience  (FRA:MR4) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Meridian Bioscience Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (FRA:MR4) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Meridian Bioscience (FRA:MR4) Headlines

No Headlines